A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition
The serotonin reuptake transporter (SERT) is responsible for the removal and recycling of the neurotransmitter…
CertaraApril 30, 2025
Model-Based Meta-Analysis (MBMA) for Relative Treatment Effects and Absolute Outcomes: A Focus on Concepts and Applications
Vice President, MBMA Capability Lead, Certara Drug Development Solutions Matt advances the integration of published…
CertaraApril 10, 2025
Model-Based Meta-Analysis for All Phases of Drug Development: Capturing the Full Potential of Published Clinical Trial Outcomes [APAC Webinar]
Vice President, Quantitative Science Services, Certara Matt advances the integration of published clinical outcomes data…
CertaraApril 3, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement
This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…
CertaraFebruary 25, 2025
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
CertaraJanuary 9, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
CertaraJanuary 8, 2025
Using MBMA to run virtual “head-to-head trials”
Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…
CertaraApril 21, 2023
